Home use of an artificial beta cell in type 1 diabetes

Hood Thabit, Martin Tauschmann, Janet M Allen, Lalantha Leelarathna, Sara Hartnell, Malgorzata E Wilinska, Carlo L Acerini, Sibylle Dellweg, Carsten Benesch, Lutz Heinemann, Julia K Mader, Manuel Holzer, Harald Kojzar, Jane Exall, James Yong, Jennifer Pichierri, Katharine D Barnard, Craig Kollman, Peiyao Cheng, Peter C HindmarshFiona M Campbell, Sabine Arnolds, Thomas R Pieber, Mark L Evans, David B Dunger, Roman Hovorka, Helen Murphy, APCam Consortium

Research output: Contribution to journalArticlepeer-review

377 Citations (Scopus)


BACKGROUND: The feasibility, safety, and efficacy of prolonged use of an artificial beta cell (closed-loop insulin-delivery system) in the home setting have not been established. 

METHODS: In two multicenter, crossover, randomized, controlled studies conducted under free-living home conditions, we compared closed-loop insulin delivery with sensor-augmented pump therapy in 58 patients with type 1 diabetes. The closed-loop system was used day and night by 33 adults and overnight by 25 children and adolescents. Participants used the closed-loop system for a 12-week period and sensor-augmented pump therapy (control) for a similar period. The primary end point was the proportion of time that the glucose level was between 70 mg and 180 mg per deciliter for adults and between 70 mg and 145 mg per deciliter for children and adolescents. 

RESULTS: Among adults, the proportion of time that the glucose level was in the target range was 11.0 percentage points (95% confidence interval [CI], 8.1 to 13.8) greater with the use of the closed-loop system day and night than with control therapy (P<0.001). The mean glucose level was lower during the closed-loop phase than during the control phase (difference, -11 mg per deciliter; 95% CI, -17 to -6; P<0.001), as were the area under the curve for the period when the glucose level was less than 63 mg per deciliter (39% lower; 95% CI, 24 to 51; P<0.001) and the mean glycated hemoglobin level (difference, -0.3%; 95% CI, -0.5 to -0.1; P=0.002). Among children and adolescents, the proportion of time with the nighttime glucose level in the target range was higher during the closed-loop phase than during the control phase (by 24.7 percentage points; 95% CI, 20.6 to 28.7; P<0.001), and the mean nighttime glucose level was lower (difference, -29 mg per deciliter; 95% CI, -39 to -20; P<0.001). The area under the curve for the period in which the day-and-night glucose levels were less than 63 mg per deciliter was lower by 42% (95% CI, 4 to 65; P=0.03). Three severe hypoglycemic episodes occurred during the closed-loop phase when the closed-loop system was not in use. 

CONCLUSIONS: Among patients with type 1 diabetes, 12-week use of a closed-loop system, as compared with sensor-augmented pump therapy, improved glucose control, reduced hypoglycemia, and, in adults, resulted in a lower glycated hemoglobin level. (Funded by the JDRF and others; AP@home04 and APCam08 ClinicalTrials.gov numbers, NCT01961622 and NCT01778348.). 

Original languageEnglish
Pages (from-to)2129-2140
Number of pages12
JournalNew England Journal of Medicine
Publication statusPublished - 26 Nov 2015


  • Adolescent
  • Adult
  • Algorithms
  • Child
  • Cross-Over Studies
  • Diabetes Mellitus, Type 1
  • Equipment Design
  • Female
  • Hemoglobin A, Glycosylated
  • Humans
  • Hypoglycemia
  • Hypoglycemic Agents
  • Infusion Pumps, Implantable
  • Insulin
  • Insulin Infusion Systems
  • Male
  • Middle Aged

Cite this